Literature DB >> 8883409

Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.

J J Pink1, M M Bilimoria, J Assikis, V C Jordan.   

Abstract

The development of antioestrogen resistance is a major clinical obstacle encountered in the treatment of breast cancer. By long-term growth in oestrogen-free medium, we have derived an oestrogen-independent, anti-oestrogen resistant cell line from the oestrogen receptor (ER)-positive, oestrogen-dependent T47D human breast cancer cell line. This cell line grows maximally in oestrogen-free medium and is resistant to all tested antioestrogens. This cell line does not express any measurable amounts of ER mRNA or protein and, in short-term studies, these cells show no response to either oestrogens or antioestrogens. However, return of these cells to oestrogen-containing medium for more than 8 weeks resulted in the re-expression of ER mRNA and protein. Subsequent limiting dilution subcloning of the T47D:C4 line revealed two phenotypically distinct clones, one which did not express measurable ER after long-term growth in oestrogen-containing medium and one which expressed ER mRNA and protein after a number of weeks in oestrogen-containing medium. In the absence of oestrogen, both types of cells are ER-negative as determined by Northern and Western blotting and lack of any oestrogen-dependent responses. The clone which re-expresses the ER (T47D:C4:5W) now responds to E2 with a 50% increase in growth and a 30-fold induction of an ER-responsive luciferase reporter construct. Long-term growth of the stably ER-negative clone (T47D:C4:2W) causes no measurable oestrogen-mediated responses, as assessed by ER expression, growth stimulation or luciferase induction. Interestingly, ER mRNA can be detected in both cell types by using reverse transcriptase-polymerase chain reaction (RT-PCR). This suggests that the ER mRNA present in the T47D:C4:2W clone is either inefficiently translated or is present at such a low level as to be functionally irrelevant. These novel clonal cell lines will prove to be invaluable in the study of the regulation of ER expression and regulatory pathways leading to oestrogen-independent growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883409      PMCID: PMC2075946          DOI: 10.1038/bjc.1996.521

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  Establishment and characterization of a cell line of human breast carcinoma origin.

Authors:  I Keydar; L Chen; S Karby; F R Weiss; J Delarea; M Radu; S Chaitcik; H J Brenner
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

2.  Estrogen receptor in a human cell line (MCF-7) from breast carcinoma.

Authors:  S C Brooks; E R Locke; H D Soule
Journal:  J Biol Chem       Date:  1973-09-10       Impact factor: 5.157

3.  A simple, rapid, and sensitive DNA assay procedure.

Authors:  C Labarca; K Paigen
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

Review 4.  The cellular response of human breast cancer to estrogen.

Authors:  G Wilding; M E Lippman; R B Dickson
Journal:  Prog Clin Biol Res       Date:  1988

5.  Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin.

Authors:  A M Nardulli; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1988-04       Impact factor: 4.736

6.  Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D).

Authors:  D Chalbos; F Vignon; I Keydar; H Rochefort
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

7.  The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.

Authors:  M Lippman; G Bolan; K Huff
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

8.  Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies.

Authors:  K B Horwitz; G R Freidenberg
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

9.  Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance.

Authors:  K B Horwitz; M B Mockus; B A Lessey
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

10.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

Authors:  G M Clark; C K Osborne; W L McGuire
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

View more
  33 in total

1.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

2.  Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.

Authors:  Philipp Y Maximov; Cynthia B Myers; Ramona F Curpan; Joan S Lewis-Wambi; V Craig Jordan
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

3.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

4.  Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.

Authors:  Paola Rizzo; Haixi Miao; Gwendolyn D'Souza; Clodia Osipo; Lynda L Song; Jieun Yun; Huiping Zhao; Joaquina Mascarenhas; Debra Wyatt; Giovanni Antico; Lu Hao; Katharine Yao; Prabha Rajan; Chindo Hicks; Kalliopi Siziopikou; Suzanne Selvaggi; Amina Bashir; Deepali Bhandari; Adriano Marchese; Urban Lendahl; Jian-Zhong Qin; Debra A Tonetti; Kathy Albain; Brian J Nickoloff; Lucio Miele
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

Review 6.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

7.  A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes.

Authors:  Eric A Ariazi; John C Taylor; Michael A Black; Emmanuelle Nicolas; Michael J Slifker; Diana J Azzam; Jeff Boyd
Journal:  Mol Cancer Res       Date:  2016-11-15       Impact factor: 5.852

Review 8.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

9.  Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.

Authors:  Yiyun Zhang; Huiping Zhao; Szilard Asztalos; Michael Chisamore; Yasmin Sitabkhan; Debra A Tonetti
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

Review 10.  Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

Authors:  Antoinette R Tan; Gabriela Alexe; Michael Reiss
Journal:  Breast Cancer Res Treat       Date:  2008-10-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.